Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

Moderna (MRNA) shares have been under pressure lately, slipping around 8% over the past month. Investors continue to weigh up ...

US pharma giant Pfizer has provided a reminder of the merits of mRNA-based vaccines as health leaders in the USA continue to question their safety.

The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Q3 earnings beat estimates but pipeline setback and lower 2025 guidance raise concerns. Full analysis of results and outlook.

Moderna (MRNA) announced on Wednesday that it has completed its domestic end-to-end mRNA manufacturing network with the ...

San Diego-based RNA biotech Arcturus is doubling down on mRNA therapeutics and stepping back from earlier-stage vaccine work in an effort to prioritize spending and extend its cash runway. In a brief ...

The MarketWatch News Department was not involved in the creation of this content. -- GEMORNA is world's first generative AI platform purpose-built for mRNA design and optimization, demonstrating state ...

Sensible Biotechnologies Slashes Time Taken to Optimize Novel Cell-Based mRNA Therapeutics by More Than 90% with AI Platform Built on NVIDIA Technology Sensible Biotechnologies, a biotechnology ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Strand Therapeutics today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising ...